AbbVie Inc.
AbbVie Updates 2026 Earnings Guidance Due to Acquired IPR&D and Milestones Expense
Summary
AbbVie Inc. has updated its 2026 earnings guidance to include an expected acquired IPR&D and milestones expense of $744 million for the first quarter, resulting in an unfavorable impact of $0.41 on both GAAP and non-GAAP diluted earnings per share. The company's full-year 2026 adjusted diluted EPS guidance range is now $13.96 - $14.16, and the first quarter 2026 adjusted diluted EPS guidance range is $2.56 - $2.60, both including the impact of this expense. The company does not forecast this expense due to the uncertainty of future transactions.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement